Pharma Company asked to stop manufacturing after samples found NSQ: Punjab

Last Updated on January 4, 2024 by The Health Master

Manufacturing activity stopped

A pharmaceutical company in Punjab, India, has been instructed to cease all manufacturing operations due to concerns about the quality of its products.

This action was taken following an alert from the World Health Organization (WHO) indicating that samples collected from the company’s premises did not meet the required standards.

The Lok Sabha, the lower house of India’s Parliament, was informed about this development.

Investigation and Response:

The Central Drugs Standard Control Organisation (CDSCO), in collaboration with the State Drugs Authority of Punjab, conducted a comprehensive investigation into the matter.

The focus of the investigation was M/s QP Pharmachem Ltd., a pharmaceutical company based in Punjab.

The aim was to assess the quality of their products and manufacturing practices.

WHO Alert and Specifics:

Bharati Pravin Pawar, the Minister of State for Health, provided a written response in the Lok Sabha.

According to her, the WHO had issued a medical product alert regarding a particular batch of Guaifenesin syrup manufactured in India.

This alert was specifically related to the use of this syrup in the Marshall Islands and the Federated States of Micronesia.

Investigation Findings:

The investigation carried out by CDSCO and the Punjab State Drugs Authority revealed concerning results.

Samples of drugs collected from the manufacturing premises of M/s QP Pharmachem Ltd were tested and analyzed.

Unfortunately, the findings were that these samples did not meet the required quality standards set out in the Drugs and Cosmetics Act of 1940.

In simpler terms, the drugs were found to be of lower quality than expected.

Immediate Action Taken:

In response to the investigation’s findings, the Punjab State Licensing Authority took decisive action.

The pharmaceutical company, M/s QP Pharmachem Ltd, was directed to halt all manufacturing activities without delay.

This step was taken to prevent the production of potentially substandard drugs and to ensure the safety of consumers.

Conclusion:

In summary, a pharmaceutical company in Punjab, India, faced a halt in its manufacturing operations due to the substandard quality of its products.

The action was taken following an alert from the World Health Organization.

The investigation highlighted the importance of maintaining strict quality standards in the pharmaceutical industry to ensure the safety and well-being of consumers.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model, to rewrite and present the news / article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

• Bulk drug import from China continues to rise in 5 years
  December 25, 2024
• Stay action against Pharma units manufacturing Nutraceuticals: High Court
  December 25, 2024
• NPPA fixed retail price of 7 formulations: December 2024
  December 24, 2024
• Revised Schedule M: Industry seeks balance between Quality and Viability
  December 24, 2024
• FDA Karnataka enters a New Era of Food and Drug Safety
  December 24, 2024
• Key Notes on Revised Schedule M: Point No. 13 – Equipment
  December 24, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: